AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
About this trial
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.
Eligibility criteria
Qualifiers
Adults aged ≥ 18 years.
HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the *2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults*.
HCM phenocopy cohort: Adults with an LV wall thickness ≥ 13 mm at any site on echocardiography.
Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
15,000 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov